State Street SPDR S&P Biotech ETF

State Street·Tracks S&P Biotechnology Select Industry Index·Inception Jan 31, 2006

Expense ratio
0.35%
35.0 bps
Net assets
$11.40B
TTM yield
0.36%
Last price
$156.82
as of Sep 10, 2026

Composite score

81/ 100
Cost65

Based on a 0.35% expense ratio.

Liquidity100

Based on $11.40B in net assets.

Concentration89

Top-10 holdings represent 18.0% of net assets.

Tax efficiency85

Healthcare base · ETF wrapper · 0.36% TTM yield.

The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. Seemethodologyfor formulas, thetracking-qualitypartial-coverage rationale, and the dimensions we deliberatelydon't score(methodology v0.5.1).

Use XBI in our tools

Top holdings

159 total holdings· as of Jun 30, 2026
#HoldingWeight
1State Street Global Advisors5.87%
2Apogee Therapeutics Inc1.49%
3Moderna Inc1.41%
4Twist Bioscience Corp1.41%
5Oruka Therapeutics Inc1.38%
6Kymera Therapeutics Inc1.36%
7Viking Therapeutics Inc1.30%
8Praxis Precision Medicines Inc1.29%
9Erasca Inc1.27%
10Revolution Medicines Inc1.20%

Compare XBI with another fund

Or skim the closest-overlap funds below.

Similar ETFs by holdings overlap

Open XBI at a brokerage

Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodologyand funding disclosure.

Holdings sourced fromSEC Form N-PORT-P(accession 0001410368-26-089400).